At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓Received ≥2 prior doses of Comirnaty or Moderna COVID-19 vaccine (Spikevax), with last dose ≥6 months before screening
- ✓Negative SARS-CoV-2 RT-PCR at screening
- ✓Healthy or medically stable with normal labs, vitals, and physical exam
- ✕Positive pregnancy test or breastfeeding
- ✕Fever (≥38.0°C or ≥100.4°F) within 72 hours before vaccination or suspected COVID-19 symptoms
- ✕History of SARS-CoV-2 infection or COVID-19 within 6 months before screening
- ✕HIV, hepatitis B, or hepatitis C (documented history or positive test at screening)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
In Brief
A Phase 1 clinical trial evaluating CV0501 (3 μg), CV0501 (6 μg), and 5 other interventions for COVID-19 and SARS-CoV-2. Completed, enrolled 185 participants across 17 sites in 3 countries.
Detailed Summary
Prevention of COVID-19 caused by SARS-CoV-2.
Study Details
Timeline
Interventions
Study vaccine was administered as a single intramuscular injection.
Study vaccine was administered as a single intramuscular injection.
Study vaccine was administered as a single intramuscular injection.
Study vaccine was administered as a single intramuscular injection.
Study vaccine was administered as a single intramuscular injection.
Study vaccine was administered as a single intramuscular injection.
Study vaccine was administered as a single intramuscular injection.